Rick has over 30 years of experience in business management and new business/technology development in the life science industry. He has held executive leadership positions in multinational corporations as well as early stage ventures. He retired from Millipore in Dec 2010, where he was Vice President of the Drug Discovery & Development business unit from mid 2006 through 2010. Millipore was acquired by Merck KGaA in mid-2010, and Rick supported several aspects of the integration process with EMD and Serono.
Prior to Millipore, Rick was the President of LINCO Research, a company focused on immunoassay kits and services for life science research. LINCO was a leader in the development of multiplex assays for the Luminex platform. Rick started his career in biotechnology/life science at Monsanto, where he held several technology and business management positions of increasing responsibility, including Mgr, R&D, Dir. Commercial/Business Development, Dir. Strategic Planning and Dir. International Markets. Currently, Rick serves as CEO of Apertus Pharmaceuticals, an early stage venture that focuses on generic API manufacturing (including controlled substances) and the production of finished dose formulations.
Rick received his PhD (Biochemistry) from the University of Illinois and his executive MBA from Washington University in St. Louis. He was an American Cancer Society post-doctoral fellow at the University of Wisconsin. He obtained his B.S. in chemistry from Central College in Pella, Iowa.